Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
10 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-phase-12-expansion-for-ide397-and-trodelvy-combination-in-mtap-deletion-urothelial-cancer-302425193.html
31 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-302415020.html
26 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-announces-oral-presentation-at-the-new-drugs-on-the-horizon-series-at-aacr-2025-for-ide275-gsk959-a-phase-1-werner-helicase-inhibitor-302411575.html
03 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-collaboration-with-attmos-to-accelerate-aiml-enabled-drug-discovery-for-unprecedented-first-in-class-oncology-targets-302389173.html
14 Feb 2025
// BIOSPACE
https://www.biospace.com/business/amgen-ideaya-call-it-quits-on-cancer-combo
13 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-announces-further-gilead-sciences-clinical-study-collaboration-evaluating-combination-of-trodelvy-and-ide397-in-mtap-deletion-nsclc-302375663.html
Details:
IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of primary uveal melanoma.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Brand Name: IDE196
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2025
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Announces Successful FDA Type D Meeting on Phase 3 Design for Darovasertib
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of primary uveal melanoma.
Product Name : IDE196
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2025
Details:
IDE397 is first-in-class, small molecule MAT2A inhibitor, being evaluating in combination with Trodelvy in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer.
Lead Product(s): IDE-397,Sacituzumab Govitecan
Therapeutic Area: Oncology Brand Name: IDE397
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : IDE-397,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Expands IDE397-Trodelvy Study for MTAP-Deleted Urothelial Cancer
Details : IDE397 is first-in-class, small molecule MAT2A inhibitor, being evaluating in combination with Trodelvy in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer.
Product Name : IDE397
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2025
Details:
IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Brand Name: IDE196
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Gets FDA Breakthrough Status for Darovasertib in Uveal Melanoma
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma.
Product Name : IDE196
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2025
Details:
The collaboration will integrate IDEAYA's drug discovery across multiple first-in-class oncology targets with ATTMOS's computational chemistry method development & software development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: ATTMOS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : ATTMOS
Deal Size : Undisclosed
Deal Type : Collaboration
Ideaya, Attmos Partner for AI/ML-Driven Drug Discovery in Oncology
Details : The collaboration will integrate IDEAYA's drug discovery across multiple first-in-class oncology targets with ATTMOS's computational chemistry method development & software development.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 03, 2025
Details:
The collaboration aims to evaluate the efficacy and safety of IDE397, potential first-in-class, small molecule MAT2A inhibitor, in combination with Trodelvy to treat MTAP-deletion NSCLC.
Lead Product(s): IDE397,Sacituzumab Govitecan
Therapeutic Area: Oncology Brand Name: IDE397
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2025
Lead Product(s) : IDE397,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
IDEAYA, Gilead Expand Study on Trodelvy & IDE397 in MTAP-Deletion NSCLC
Details : The collaboration aims to evaluate the efficacy and safety of IDE397, potential first-in-class, small molecule MAT2A inhibitor, in combination with Trodelvy to treat MTAP-deletion NSCLC.
Product Name : IDE397
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 13, 2025
Details:
IDE251 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7. It is being evaluated for the treatment of 8p11 amplified breast & lung cancer.
Lead Product(s): IDE251
Therapeutic Area: Oncology Brand Name: IDE251
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : IDE251
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Selects IDE251 Targeting KAT6/7 Amplification in Breast and Lung Cancers
Details : IDE251 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7. It is being evaluated for the treatment of 8p11 amplified breast & lung cancer.
Product Name : IDE251
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Details:
IDE161 is a small molecule inhibitor drug candidate targeting PARG, which is being evaluated in combination with Keyutra for the treatment of Endometrial Cancer.
Lead Product(s): IDE161,Pembrolizumab
Therapeutic Area: Oncology Brand Name: IDE161
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2024
Lead Product(s) : IDE161,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Begins Phase 1 Trial for IDE161 with KEYTRUDA® in Endometrial Cancer
Details : IDE161 is a small molecule inhibitor drug candidate targeting PARG, which is being evaluated in combination with Keyutra for the treatment of Endometrial Cancer.
Product Name : IDE161
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Details:
IDE892 is a potential best-in-class MTA-cooperative PRMT5 inhibitor, which is currently being evaluated for the treatment of MTAP-deletion solids tumors.
Lead Product(s): IDE892
Therapeutic Area: Oncology Brand Name: IDE892
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : IDE892
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Nominates IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
Details : IDE892 is a potential best-in-class MTA-cooperative PRMT5 inhibitor, which is currently being evaluated for the treatment of MTAP-deletion solids tumors.
Product Name : IDE892
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Details:
The collaboration aims to focus on the clinical development of IDE161, a small molecule inhibitor targeting PARG, in combination with Keyutra for the treatment of Endometrial Cancer.
Lead Product(s): IDE161,Pembrolizumab
Therapeutic Area: Oncology Brand Name: IDE161
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 03, 2024
Lead Product(s) : IDE161,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
IDEAYA Announces Collaboration to Evaluate IDE161 with Keytruda in Endometrial Cancer
Details : The collaboration aims to focus on the clinical development of IDE161, a small molecule inhibitor targeting PARG, in combination with Keyutra for the treatment of Endometrial Cancer.
Product Name : IDE161
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 03, 2024
Details:
IDE034 is a promising potential first-in class B7H3/PTK7 topo-I-payload bispecific ADC, which has demonstrated robust monotherapy tumor regressions in multiple preclinical models.
Lead Product(s): IDE034
Therapeutic Area: Oncology Brand Name: IDE034
Study Phase: PreclinicalProduct Type: Other Large Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 11, 2024
Lead Product(s) : IDE034
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Advances IDE034 as First-in-Class Bispecific ADC with Biocytogen Deal
Details : IDE034 is a promising potential first-in class B7H3/PTK7 topo-I-payload bispecific ADC, which has demonstrated robust monotherapy tumor regressions in multiple preclinical models.
Product Name : IDE034
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 11, 2024
ABOUT THIS PAGE